School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
South Western Sydney Metabolic Rehabilitation and Bariatric Program, Camden and Campbelltown Hospitals, Campbelltown, New South Wales, Australia.
BMC Endocr Disord. 2021 Nov 14;21(1):227. doi: 10.1186/s12902-021-00887-3.
Although there is a strong association between obesity and obstructive sleep apnoea (OSA), the effects of OSA and CPAP therapy on weight loss are less well known. The aim of this study in adults with class 3 obesity attending a multidisciplinary weight management program was to assess the relationship between OSA and CPAP usage, and 12-month weight change.
A retrospective cohort study of all patients commencing an intensive multidisciplinary publicly funded weight management program in Sydney, Australia, between March 2018 and March 2019. OSA was diagnosed using laboratory overnight sleep studies. Demographic and clinical data, and use of CPAP therapy was collected at baseline and 12 months. CPAP use was confirmed if used ≥4 h on average per night on download.
Of the 178 patients who joined the program, 111 (62.4 %) completed 12 months in the program. At baseline, 63.1 % (n=70) of patients had OSA, of whom 54.3 % (n=38) were using CPAP. The non-OSA group had more females compared to the OSA with CPAP group and OSA without CPAP group (90.2 % vs. 57.9 % and 62.5 %, respectively; p=0.003), but there were no significant baseline differences in BMI (50.4±9.3 vs. 52.1±8.7 and 50.3±9.5 kg/m, respectively; p=0.636). There was significant weight loss across all three groups at 12 months. However, there were no statistically significant differences across groups in the percentage of body weight loss (OSA with CPAP: 6.3±5.6 %, OSA without CPAP: 6.8±6.9 %, non-OSA: 7.2±6.5 %; p=0.844), or the proportion of patients who achieved ≥5 % body weight loss (OSA with CPAP: 57.9 %, OSA without CPAP: 59.4 %, non-OSA: 65.9 %; p=0.743). In patients with T2DM, there was a significant reduction in HbA1c from baseline to 12 months (7.8±1.7 % to 7.3±1.4 %, p=0.03), with no difference between groups (p=0.997).
This multidisciplinary weight management program resulted in significant weight loss at 12 months, regardless of OSA diagnosis or CPAP use in adults with class 3 obesity. Larger studies are needed to further investigate the effects of severity of OSA status and CPAP use in weight management programs. Until completed, this study suggests that the focus should remain on implementing lifestyle changes and weight management regardless of OSA status.
虽然肥胖与阻塞性睡眠呼吸暂停(OSA)之间存在很强的关联,但 OSA 及其 CPAP 治疗对体重减轻的影响却鲜为人知。本研究旨在评估患有 3 类肥胖的成年人的 OSA 与 CPAP 使用及其 12 个月体重变化之间的关系,这些患者参加了一个多学科的体重管理计划。
这是一项在澳大利亚悉尼参加密集型多学科公共资助体重管理计划的所有患者的回顾性队列研究,研究时间为 2018 年 3 月至 2019 年 3 月。使用实验室过夜睡眠研究来诊断 OSA。在基线和 12 个月时收集人口统计学和临床数据以及 CPAP 治疗的使用情况。如果在下载时平均每晚使用 CPAP 治疗≥4 小时,则确认 CPAP 治疗的使用情况。
在加入该计划的 178 名患者中,有 111 名(62.4%)完成了该计划的 12 个月。在基线时,63.1%(n=70)的患者患有 OSA,其中 54.3%(n=38)正在使用 CPAP。非 OSA 组与 OSA 合并 CPAP 组和 OSA 无 CPAP 组相比,女性比例更高(90.2%比 57.9%和 62.5%,分别;p=0.003),但 BMI 无显著基线差异(50.4±9.3 vs. 52.1±8.7 和 50.3±9.5 kg/m,分别;p=0.636)。所有三组在 12 个月时均有明显的体重减轻。但是,各组之间体重减轻的百分比没有统计学差异(OSA 合并 CPAP:6.3±5.6%,OSA 无 CPAP:6.8±6.9%,非 OSA:7.2±6.5%;p=0.844),或者达到≥5%体重减轻的患者比例也没有差异(OSA 合并 CPAP:57.9%,OSA 无 CPAP:59.4%,非 OSA:65.9%;p=0.743)。在患有 2 型糖尿病的患者中,HbA1c 从基线到 12 个月显著降低(7.8±1.7%至 7.3±1.4%,p=0.03),各组之间没有差异(p=0.997)。
无论患有 3 类肥胖的成年人是否患有 OSA 或使用 CPAP,该多学科体重管理计划在 12 个月时均会导致体重明显减轻。需要更大规模的研究来进一步探讨 OSA 严重程度和 CPAP 在体重管理计划中的使用的影响。在完成这些研究之前,本研究表明,应将重点仍然放在实施生活方式改变和体重管理上,而不论 OSA 状况如何。